<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Chron Obstruct Pulmon Dis</journal-id><journal-id journal-id-type="iso-abbrev">Int J Chron Obstruct Pulmon Dis</journal-id><journal-id journal-id-type="publisher-id">International Journal of COPD</journal-id><journal-title-group><journal-title>International Journal of Chronic Obstructive Pulmonary Disease</journal-title></journal-title-group><issn pub-type="ppub">1176-9106</issn><issn pub-type="epub">1178-2005</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27785010</article-id><article-id pub-id-type="pmc">5066848</article-id><article-id pub-id-type="doi">10.2147/COPD.S111408</article-id><article-id pub-id-type="publisher-id">copd-11-2543</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hashimoto</surname><given-names>Shu</given-names></name><xref ref-type="aff" rid="af1-copd-11-2543">1</xref><xref ref-type="corresp" rid="c1-copd-11-2543"></xref></contrib><contrib contrib-type="author"><name><surname>Ikeuchi</surname><given-names>Hisataro</given-names></name><xref ref-type="aff" rid="af2-copd-11-2543">2</xref></contrib><contrib contrib-type="author"><name><surname>Murata</surname><given-names>Shujiro</given-names></name><xref ref-type="aff" rid="af2-copd-11-2543">2</xref></contrib><contrib contrib-type="author"><name><surname>Kitawaki</surname><given-names>Tetsuji</given-names></name><xref ref-type="aff" rid="af2-copd-11-2543">2</xref></contrib><contrib contrib-type="author"><name><surname>Ikeda</surname><given-names>Kimitoshi</given-names></name><xref ref-type="aff" rid="af2-copd-11-2543">2</xref></contrib><contrib contrib-type="author"><name><surname>Banerji</surname><given-names>Donald</given-names></name><xref ref-type="aff" rid="af3-copd-11-2543">3</xref></contrib></contrib-group><aff id="af1-copd-11-2543"><label>1</label>Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan</aff><aff id="af2-copd-11-2543"><label>2</label>Novartis Pharma KK, Minato-ku, Tokyo, Japan</aff><aff id="af3-copd-11-2543"><label>3</label>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA</aff><author-notes><corresp id="c1-copd-11-2543">Correspondence: Shu Hashimoto, Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, 30-1, Ohyaguchikamimachi, Itabashi-ku, Tokyo 173-8610, Japan, Tel +81 3 3972 7552, Email <email>hashimoto.shu@nihon-u.ac.jp</email></corresp></author-notes><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>11</day><month>10</month><year>2016</year></pub-date><volume>11</volume><fpage>2543</fpage><lpage>2551</lpage><permissions><copyright-statement>© 2016 Hashimoto et al. This work is published and licensed by Dove Medical Press Limited</copyright-statement><copyright-year>2016</copyright-year><license><license-p>The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title><offsets xml_i="4113" xml_f="4123" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="4134" xml_f="4212" txt_i="22" txt_f="100">COPD-related deaths are increasing in Japan, with ~5.3 million people at risk.</offsets></p></sec><sec><title><offsets xml_i="4234" xml_f="4241" txt_i="102" txt_f="109">Methods</offsets></title><p><offsets xml_i="4252" xml_f="4608" txt_i="110" txt_f="466">The SHINE was a 26-week, multicenter, randomized, double-blind, parallel-group study that evaluated safety and efficacy of indacaterol (IND)/glycopyrronium (GLY) 110/50 μg once daily (od) compared with GLY 50 μg od, IND 150 μg od, open-label tiotropium (TIO) 18 μg od, and placebo. The primary end point was trough forced expiratory volume in 1 second (FEV</offsets><sub><offsets xml_i="4613" xml_f="4614" txt_i="466" txt_f="467">1</offsets></sub><offsets xml_i="4620" xml_f="4672" txt_i="467" txt_f="519">) at Week 26. Other key end points included peak FEV</offsets><sub><offsets xml_i="4677" xml_f="4678" txt_i="519" txt_f="520">1</offsets></sub><offsets xml_i="4684" xml_f="4714" txt_i="520" txt_f="550">, area under the curve for FEV</offsets><sub><offsets xml_i="4719" xml_f="4720" txt_i="550" txt_f="551">1</offsets></sub><offsets xml_i="4726" xml_f="4757" txt_i="551" txt_f="582"> from 5 minutes to 4 hours (FEV</offsets><sub><offsets xml_i="4762" xml_f="4763" txt_i="582" txt_f="583">1</offsets></sub><offsets xml_i="4769" xml_f="4773" txt_i="583" txt_f="587"> AUC</offsets><sub><offsets xml_i="4778" xml_f="4787" txt_i="587" txt_f="596">5 min–4 h</offsets></sub><offsets xml_i="4793" xml_f="4970" txt_i="596" txt_f="773">), Transition Dyspnea Index focal score, St George’s Respiratory Questionnaire total score, and safety. Here, we present efficacy and safety of IND/GLY in the Japanese subgroup.</offsets></p></sec><sec><title><offsets xml_i="4992" xml_f="4999" txt_i="775" txt_f="782">Results</offsets></title><p><offsets xml_i="5010" xml_f="5189" txt_i="783" txt_f="962">Of 2,144 patients from the SHINE study, 182 (8.5%) were Japanese and randomized to IND/GLY (n=42), IND (n=41), GLY (n=40), TIO (n=40), or placebo (n=19). Improvement in trough FEV</offsets><sub><offsets xml_i="5194" xml_f="5195" txt_i="962" txt_f="963">1</offsets></sub><offsets xml_i="5201" xml_f="5417" txt_i="963" txt_f="1179"> from baseline was 190 mL with IND/GLY and treatment differences versus IND (90 mL), GLY (100 mL), TIO (90 mL), and placebo (280 mL) along with a rapid onset of action at Week 26. IND/GLY showed an improvement in FEV</offsets><sub><offsets xml_i="5422" xml_f="5423" txt_i="1179" txt_f="1180">1</offsets></sub><offsets xml_i="5429" xml_f="5433" txt_i="1180" txt_f="1184"> AUC</offsets><sub><offsets xml_i="5438" xml_f="5447" txt_i="1184" txt_f="1193">5 min–4 h</offsets></sub><offsets xml_i="5453" xml_f="5482" txt_i="1193" txt_f="1222"> versus all comparators (all </offsets><italic><offsets xml_i="5490" xml_f="5491" txt_i="1222" txt_f="1223">P</offsets></italic><offsets xml_i="5500" xml_f="5770" txt_i="1223" txt_f="1490">&lt;0.05). All the treatments were well tolerated and showed comparable effect on Transition Dyspnea Index focal score and St George’s Respiratory Questionnaire total score. The effect of IND/GLY in the Japanese subgroup was consistent to overall SHINE study population.</offsets></p></sec><sec><title><offsets xml_i="5792" xml_f="5802" txt_i="1492" txt_f="1502">Conclusion</offsets></title><p><offsets xml_i="5813" xml_f="6041" txt_i="1503" txt_f="1731">IND/GLY demonstrated superior efficacy and comparable safety compared with its monocomponents, open-label TIO, and placebo and may be used as a treatment option for the management of moderate-to-severe COPD in Japanese patients.</offsets></p></sec></abstract><kwd-group><title>Keywords</title><kwd>SHINE study</kwd><kwd>Japanese subgroup</kwd><kwd>COPD</kwd><kwd>indacaterol/glycopyrronium</kwd><kwd>open-label tiotropium</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title><offsets xml_i="6300" xml_f="6312" txt_i="1740" txt_f="1752">Introduction</offsets></title><p><offsets xml_i="6323" xml_f="6474" txt_i="1753" txt_f="1904">COPD was the tenth most common cause of disease-related deaths in Japan in 2014, and it was found that the number of COPD-related deaths is increasing.</offsets><xref rid="b1-copd-11-2543" ref-type="bibr"><offsets xml_i="6518" xml_f="6519" txt_i="1904" txt_f="1905">1</offsets></xref><offsets xml_i="6526" xml_f="6875" txt_i="1905" txt_f="2254"> An epidemiological survey in Japanese population revealed that the prevalence of physician-diagnosed COPD in Japan is increasing, and ~8.6% of the patients aged ≥40 years are suffering from COPD. An estimated population of 5.3 million Japanese are now at risk of developing COPD; however, only a small proportion (9.4%) were diagnosed to have COPD.</offsets><xref rid="b2-copd-11-2543" ref-type="bibr"><offsets xml_i="6919" xml_f="6920" txt_i="2254" txt_f="2255">2</offsets></xref><offsets xml_i="6927" xml_f="6928" txt_i="2255" txt_f="2256">,</offsets><xref rid="b3-copd-11-2543" ref-type="bibr"><offsets xml_i="6972" xml_f="6973" txt_i="2256" txt_f="2257">3</offsets></xref></p><p><offsets xml_i="6987" xml_f="7137" txt_i="2258" txt_f="2408">Decline in quality of life due to breathlessness is the major challenge in the management of COPD that demands sustained improvement in lung function.</offsets><xref rid="b4-copd-11-2543" ref-type="bibr"><offsets xml_i="7181" xml_f="7182" txt_i="2408" txt_f="2409">4</offsets></xref><offsets xml_i="7189" xml_f="7404" txt_i="2409" txt_f="2624"> Long-acting bronchodilators of different pharmacological classes, either as monotherapy or in combination, are now the preferred choice and proven cornerstone for treating compromised airflow in patients with COPD.</offsets><xref rid="b4-copd-11-2543" ref-type="bibr"><offsets xml_i="7448" xml_f="7449" txt_i="2624" txt_f="2625">4</offsets></xref><offsets xml_i="7456" xml_f="7728" txt_i="2625" txt_f="2897"> In situations where a single bronchodilator fails to provide the desired effect, both Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy and Japanese Respiratory Society (JRS) guidelines recommend the use of a fixed-dose combination of a long-acting β</offsets><sub><offsets xml_i="7733" xml_f="7734" txt_i="2897" txt_f="2898">2</offsets></sub><offsets xml_i="7740" xml_f="7852" txt_i="2898" txt_f="3010">-agonist (LABA) and a long-acting muscarinic antagonist (LAMA) for management of symptomatic patients with COPD.</offsets><xref rid="b4-copd-11-2543" ref-type="bibr"><offsets xml_i="7896" xml_f="7897" txt_i="3010" txt_f="3011">4</offsets></xref><offsets xml_i="7904" xml_f="7905" txt_i="3011" txt_f="3012">,</offsets><xref rid="b5-copd-11-2543" ref-type="bibr"><offsets xml_i="7949" xml_f="7950" txt_i="3012" txt_f="3013">5</offsets></xref><offsets xml_i="7957" xml_f="8292" txt_i="3013" txt_f="3348"> A fixed-dose LABA/LAMA combination, indacaterol (IND)/glycopyrronium (GLY), was evaluated in 14 controlled trials as maintenance treatment for patients with COPD. Outcomes of these studies demonstrated better efficacy of IND/GLY in terms of improving lung function and quality of life, with a comparable safety profile versus placebo,</offsets><xref rid="b6-copd-11-2543" ref-type="bibr"><offsets xml_i="8336" xml_f="8337" txt_i="3348" txt_f="3349">6</offsets></xref><offsets xml_i="8344" xml_f="8345" txt_i="3349" txt_f="3350">–</offsets><xref rid="b8-copd-11-2543" ref-type="bibr"><offsets xml_i="8389" xml_f="8390" txt_i="3350" txt_f="3351">8</offsets></xref><offsets xml_i="8397" xml_f="8432" txt_i="3351" txt_f="3386"> LAMA, open-label tiotropium (TIO),</offsets><xref rid="b9-copd-11-2543" ref-type="bibr"><offsets xml_i="8476" xml_f="8477" txt_i="3386" txt_f="3387">9</offsets></xref><offsets xml_i="8484" xml_f="8797" txt_i="3387" txt_f="3700"> and a combination of LABA/inhaled corticosteroid (ICS) and salmeterol/fluticasone (50/500 μg) in patients with moderate-to-severe COPD. Most of these trials have been conducted in Caucasian patients; however, two studies, SHINE and ARISE, evaluated the efficacy of IND/GLY in a Japanese patient subgroup as well.</offsets><xref rid="b10-copd-11-2543" ref-type="bibr"><offsets xml_i="8842" xml_f="8844" txt_i="3700" txt_f="3702">10</offsets></xref><offsets xml_i="8851" xml_f="8852" txt_i="3702" txt_f="3703">,</offsets><xref rid="b11-copd-11-2543" ref-type="bibr"><offsets xml_i="8897" xml_f="8899" txt_i="3703" txt_f="3705">11</offsets></xref><offsets xml_i="8906" xml_f="9129" txt_i="3705" txt_f="3928"> In the overall population of the SHINE study, IND/GLY showed superior improvements in lung function and health status compared with placebo, IND, GLY, and open-label TIO with a similar safety profile in patients with COPD.</offsets><xref rid="b10-copd-11-2543" ref-type="bibr"><offsets xml_i="9174" xml_f="9176" txt_i="3928" txt_f="3930">10</offsets></xref><offsets xml_i="9183" xml_f="9293" txt_i="3930" txt_f="4040"> Here, we report the efficacy and safety of IND/GLY in the Japanese subgroup of patients from the SHINE study.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="9334" xml_f="9341" txt_i="4042" txt_f="4049">Methods</offsets></title><p><offsets xml_i="9352" xml_f="9466" txt_i="4050" txt_f="4164">SHINE was a 26-week, multicenter, randomized, double-blind, parallel-group, placebo- and active-controlled study (</offsets><ext-link ext-link-type="uri" xlink:href="http://www.ClinicalTrial.gov"><offsets xml_i="9538" xml_f="9559" txt_i="4164" txt_f="4185">www.ClinicalTrial.gov</offsets></ext-link><offsets xml_i="9570" xml_f="9595" txt_i="4185" txt_f="4210"> identifier NCT01202188).</offsets><xref rid="b10-copd-11-2543" ref-type="bibr"><offsets xml_i="9640" xml_f="9642" txt_i="4210" txt_f="4212">10</offsets></xref><offsets xml_i="9649" xml_f="9901" txt_i="4212" txt_f="4464"> After the eligibility assessments, patients were randomized (2:2:2:2:1) to receive once daily (od) IND/GLY 110/50 μg, IND 150 μg, GLY 50 μg, open-label TIO 18 μg, or matching placebo. IND/GLY, IND, GLY, and placebo were administered via the Breezhaler</offsets><sup><offsets xml_i="9906" xml_f="9907" txt_i="4464" txt_f="4465">®</offsets></sup><offsets xml_i="9913" xml_f="9966" txt_i="4465" txt_f="4518"> device, whereas TIO was delivered via the HandiHaler</offsets><sup><offsets xml_i="9971" xml_f="9972" txt_i="4518" txt_f="4519">®</offsets></sup><offsets xml_i="9978" xml_f="10162" txt_i="4519" txt_f="4703"> device. Men and women aged ≥40 years with moderate-to-severe stable COPD and a smoking history of ≥10 pack-years who had a postbronchodilator forced expiratory volume in 1 second (FEV</offsets><sub><offsets xml_i="10167" xml_f="10168" txt_i="4703" txt_f="4704">1</offsets></sub><offsets xml_i="10174" xml_f="10247" txt_i="4704" txt_f="4774">) ≥30% and &lt;80% of predicted normal value and a postbronchodilator FEV</offsets><sub><offsets xml_i="10252" xml_f="10253" txt_i="4774" txt_f="4775">1</offsets></sub><offsets xml_i="10259" xml_f="10957" txt_i="4775" txt_f="5470">/forced vital capacity ratio &lt;0.70 were included in the study. The key exclusion criterion was COPD exacerbation that required treatment with antibiotics, systemic steroids (oral or intravenous), or hospitalization during 6 weeks prior to screening or before randomization. During the study, salbutamol/albuterol was permitted as a rescue medication. Informed consent was taken from all the eligible patients. The study was performed in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines, and all applicable regulatory requirements and was approved by the Ministry of Health, Labor and Welfare, Japan, as well as all relevant national and local ethics review boards (</offsets><xref ref-type="supplementary-material" rid="SD1-copd-11-2543"><offsets xml_i="11020" xml_f="11028" txt_i="5470" txt_f="5478">Table S1</offsets></xref><offsets xml_i="11035" xml_f="11037" txt_i="5478" txt_f="5480">).</offsets></p><sec><title><offsets xml_i="11053" xml_f="11064" txt_i="5481" txt_f="5492">Assessments</offsets></title><p><offsets xml_i="11075" xml_f="11124" txt_i="5493" txt_f="5542">The primary end point of the study was trough FEV</offsets><sub><offsets xml_i="11129" xml_f="11130" txt_i="5542" txt_f="5543">1</offsets></sub><offsets xml_i="11136" xml_f="11149" txt_i="5543" txt_f="5556"> (mean of FEV</offsets><sub><offsets xml_i="11154" xml_f="11155" txt_i="5556" txt_f="5557">1</offsets></sub><offsets xml_i="11161" xml_f="11324" txt_i="5557" txt_f="5720"> values measured at 23 hours 15 minutes and 23 hours 45 minutes) after IND/GLY administration at Week 26 versus IND and GLY. Other key end points included peak FEV</offsets><sub><offsets xml_i="11329" xml_f="11330" txt_i="5720" txt_f="5721">1</offsets></sub><offsets xml_i="11336" xml_f="11366" txt_i="5721" txt_f="5751">, area under the curve for FEV</offsets><sub><offsets xml_i="11371" xml_f="11372" txt_i="5751" txt_f="5752">1</offsets></sub><offsets xml_i="11378" xml_f="11409" txt_i="5752" txt_f="5783"> from 5 minutes to 4 hours (FEV</offsets><sub><offsets xml_i="11414" xml_f="11415" txt_i="5783" txt_f="5784">1</offsets></sub><offsets xml_i="11421" xml_f="11425" txt_i="5784" txt_f="5788"> AUC</offsets><sub><offsets xml_i="11430" xml_f="11439" txt_i="5788" txt_f="5797">5 min–4 h</offsets></sub><offsets xml_i="11445" xml_f="11462" txt_i="5797" txt_f="5814">), and trough FEV</offsets><sub><offsets xml_i="11467" xml_f="11468" txt_i="5814" txt_f="5815">1</offsets></sub><offsets xml_i="11474" xml_f="11758" txt_i="5815" txt_f="6099"> throughout the study period. Nonspirometric analysis included the Transition Dyspnea Index (TDI) focal score and St George’s Respiratory Questionnaire (SGRQ) total score at Week 26. Safety was assessed by monitoring adverse events (AEs) and serious AEs over the 26-week study period.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="11799" xml_f="11819" txt_i="6101" txt_f="6121">Statistical analysis</offsets></title><p><offsets xml_i="11830" xml_f="11895" txt_i="6122" txt_f="6187">Data were analyzed using a linear mixed model, which included FEV</offsets><sub><offsets xml_i="11900" xml_f="11901" txt_i="6187" txt_f="6188">1</offsets></sub><offsets xml_i="11907" xml_f="11983" txt_i="6188" txt_f="6264"> as the dependent variable, treatment as an fixed effect, the variables (FEV</offsets><sub><offsets xml_i="11988" xml_f="11989" txt_i="6264" txt_f="6265">1</offsets></sub><offsets xml_i="11995" xml_f="12009" txt_i="6265" txt_f="6279">, ICS use, FEV</offsets><sub><offsets xml_i="12014" xml_f="12015" txt_i="6279" txt_f="6280">1</offsets></sub><offsets xml_i="12021" xml_f="12321" txt_i="6280" txt_f="6580"> reversibility components, and smoking status) at baseline as covariates, and centre as a random effect. The estimated treatment differences were presented as least-squares mean with standard errors and the associated 95% confidence interval. The secondary efficacy variables, which included peak FEV</offsets><sub><offsets xml_i="12326" xml_f="12327" txt_i="6580" txt_f="6581">1</offsets></sub><offsets xml_i="12333" xml_f="12338" txt_i="6581" txt_f="6586">, FEV</offsets><sub><offsets xml_i="12343" xml_f="12344" txt_i="6586" txt_f="6587">1</offsets></sub><offsets xml_i="12350" xml_f="12354" txt_i="6587" txt_f="6591"> AUC</offsets><sub><offsets xml_i="12359" xml_f="12368" txt_i="6591" txt_f="6600">5 min–4 h</offsets></sub><offsets xml_i="12374" xml_f="12386" txt_i="6600" txt_f="6612">, trough FEV</offsets><sub><offsets xml_i="12391" xml_f="12392" txt_i="6612" txt_f="6613">1</offsets></sub><offsets xml_i="12398" xml_f="12620" txt_i="6613" txt_f="6835"> over 26 weeks, TDI focal score, and SGRQ total score, were also analyzed using the same mixed model as specified for the analysis of the primary variable, with the appropriate baseline measurement included as a covariate.</offsets><xref rid="b10-copd-11-2543" ref-type="bibr"><offsets xml_i="12665" xml_f="12667" txt_i="6835" txt_f="6837">10</offsets></xref><offsets xml_i="12674" xml_f="12957" txt_i="6837" txt_f="7120"> In addition, the proportions of patients who achieved a clinically important improvement in the SGRQ and TDI focal score were analyzed using logistic regression as specified for the analysis of the primary variable, with the appropriate baseline measurement included as a covariate.</offsets></p></sec></sec><sec sec-type="results"><title><offsets xml_i="13004" xml_f="13011" txt_i="7123" txt_f="7130">Results</offsets></title><sec sec-type="intro"><title><offsets xml_i="13048" xml_f="13071" txt_i="7131" txt_f="7154">Patient characteristics</offsets></title><p><offsets xml_i="13082" xml_f="13422" txt_i="7155" txt_f="7495">Of the total 2,144 patients randomized in the SHINE study, 182 (8.5%) were Japanese and randomized to receive IND/GLY 110/50 μg (n=42), IND 110 μg (n=41), GLY 50 μg (n=40), open-label TIO 18 μg (n=40), and matching placebo (n=19). The baseline demographic and clinical characteristics of the patients were comparable across all the groups (</offsets><xref ref-type="table" rid="t1-copd-11-2543"><offsets xml_i="13467" xml_f="13474" txt_i="7495" txt_f="7502">Table 1</offsets></xref><offsets xml_i="13481" xml_f="13626" txt_i="7502" txt_f="7644">). More than 90% of the patients in the Japanese cohort were men aged &gt;68 years, and their mean percentage of predicted postbronchodilator FEV</offsets><sub><offsets xml_i="13631" xml_f="13632" txt_i="7644" txt_f="7645">1</offsets></sub><offsets xml_i="13638" xml_f="13683" txt_i="7645" txt_f="7690"> was ~60%, with only 19% reversibility of FEV</offsets><sub><offsets xml_i="13688" xml_f="13689" txt_i="7690" txt_f="7691">1</offsets></sub><offsets xml_i="13695" xml_f="14122" txt_i="7691" txt_f="8118"> after bronchodilation. More than 75% of patients had moderate-to-severe COPD according to the GOLD 2009 guidelines, and almost 10% of patients in the Japanese subgroup were having a history of COPD exacerbation in the previous year and ~25% were using ICS at baseline. In total, 160 patients (87.9%) completed the study; the major reasons for discontinuation from the study were AEs and withdrawal of consent by the patients (</offsets><xref ref-type="fig" rid="f1-copd-11-2543"><offsets xml_i="14165" xml_f="14173" txt_i="8118" txt_f="8126">Figure 1</offsets></xref><offsets xml_i="14180" xml_f="14182" txt_i="8126" txt_f="8128">).</offsets></p></sec><sec><title><offsets xml_i="14204" xml_f="14217" txt_i="8130" txt_f="8143">Lung function</offsets></title><p><offsets xml_i="14228" xml_f="14326" txt_i="8144" txt_f="8242">The primary efficacy end point of the SHINE study was achieving a 190 mL improvement in trough FEV</offsets><sub><offsets xml_i="14331" xml_f="14332" txt_i="8242" txt_f="8243">1</offsets></sub><offsets xml_i="14338" xml_f="14547" txt_i="8243" txt_f="8452"> from baseline with IND/GLY in Japanese patients. Improvement in lung function was greater in Japanese patients treated using IND/GLY compared with IND (90 mL), GLY (100 mL), TIO (90 mL), and placebo (280 mL; </offsets><xref ref-type="fig" rid="f2-copd-11-2543"><offsets xml_i="14590" xml_f="14598" txt_i="8452" txt_f="8460">Figure 2</offsets></xref><offsets xml_i="14605" xml_f="14607" txt_i="8460" txt_f="8462">).</offsets><xref rid="b10-copd-11-2543" ref-type="bibr"><offsets xml_i="14652" xml_f="14654" txt_i="8462" txt_f="8464">10</offsets></xref><offsets xml_i="14661" xml_f="14708" txt_i="8464" txt_f="8511"> The spirometric profile in terms of trough FEV</offsets><sub><offsets xml_i="14713" xml_f="14714" txt_i="8511" txt_f="8512">1</offsets></sub><offsets xml_i="14720" xml_f="14856" txt_i="8512" txt_f="8648"> with IND/GLY was superior compared with TIO and placebo on Day 2 and Week 26, with treatment differences ranging from 90 mL to 290 mL (</offsets><xref ref-type="fig" rid="f3-copd-11-2543"><offsets xml_i="14899" xml_f="14907" txt_i="8648" txt_f="8656">Figure 3</offsets></xref><offsets xml_i="14914" xml_f="14964" txt_i="8656" txt_f="8706">). IND/GLY showed greater improvements in peak FEV</offsets><sub><offsets xml_i="14969" xml_f="14970" txt_i="8706" txt_f="8707">1</offsets></sub><offsets xml_i="14976" xml_f="15118" txt_i="8707" txt_f="8849"> from 5 minutes to 4 hours compared with IND, GLY, TIO, and placebo at Week 26, with treatment differences ranging from 100 mL to 390 mL (all </offsets><italic><offsets xml_i="15126" xml_f="15127" txt_i="8849" txt_f="8850">P</offsets></italic><offsets xml_i="15136" xml_f="15146" txt_i="8850" txt_f="8857">&lt;0.01; </offsets><xref ref-type="fig" rid="f4-copd-11-2543"><offsets xml_i="15189" xml_f="15197" txt_i="8857" txt_f="8865">Figure 4</offsets></xref><offsets xml_i="15204" xml_f="15298" txt_i="8865" txt_f="8959">). In addition, an improvement in lung function was also observed with IND/GLY in terms of FEV</offsets><sub><offsets xml_i="15303" xml_f="15304" txt_i="8959" txt_f="8960">1</offsets></sub><offsets xml_i="15310" xml_f="15314" txt_i="8960" txt_f="8964"> AUC</offsets><sub><offsets xml_i="15319" xml_f="15328" txt_i="8964" txt_f="8973">5 min–4 h</offsets></sub><offsets xml_i="15334" xml_f="15459" txt_i="8973" txt_f="9098"> compared with IND, GLY, TIO, and placebo, at the end of study, with treatment differences ranging from 90 mL to 380 mL (all </offsets><italic><offsets xml_i="15467" xml_f="15468" txt_i="9098" txt_f="9099">P</offsets></italic><offsets xml_i="15477" xml_f="15487" txt_i="9099" txt_f="9106">&lt;0.05; </offsets><xref ref-type="fig" rid="f5-copd-11-2543"><offsets xml_i="15530" xml_f="15538" txt_i="9106" txt_f="9114">Figure 5</offsets></xref><offsets xml_i="15545" xml_f="15547" txt_i="9114" txt_f="9116">).</offsets></p></sec><sec><title><offsets xml_i="15569" xml_f="15594" txt_i="9118" txt_f="9143">Patient-reported outcomes</offsets></title><p><offsets xml_i="15605" xml_f="16100" txt_i="9144" txt_f="9639">Dyspnea control in terms of improvement in TDI focal score in the Japanese subgroup was comparable across all treatment groups. Treatment differences between IND/GLY versus placebo were 0.67 units and versus IND, GLY, TIO were 0.69 units, 0.03 units, and 0.65 units, respectively. A higher proportion of patients achieved a clinically meaningful improvement in the TDI focal score (≥1 unit) with IND/GLY versus IND (odds ratio [OR], 1.60), GLY (OR, 1.01), TIO (OR, 1.16), and placebo (OR, 1.15).</offsets></p><p><offsets xml_i="16107" xml_f="16649" txt_i="9640" txt_f="10182">Improvement in health status assessed via reduction in the SGRQ total score was similar across all treatment groups in the Japanese patient subgroup. Treatment differences in the SGRQ total score between IND/GLY vs placebo, IND, GLY, and TIO were −1.31 units, −0.48 units, −3.75 units, and −0.96 units, respectively. The proportion of patients achieving a clinically meaningful improvement in the SGRQ total score (≥4-unit reduction) was highest with IND/GLY compared to IND (OR, 1.69), GLY (OR, 3.13), TIO (OR, 2.36), and placebo (OR, 0.86).</offsets></p></sec><sec><title><offsets xml_i="16671" xml_f="16677" txt_i="10184" txt_f="10190">Safety</offsets></title><p><offsets xml_i="16688" xml_f="16922" txt_i="10191" txt_f="10425">The overall incidence of AEs was similar across the five treatment groups, and the lowest incidence was reported for patients treated with IND/GLY (21 (50%); IND, 27 (65.9%); GLY, 24 (60.0%); TIO, 31 (77.5%); and placebo, 12 (63.2%); </offsets><xref ref-type="table" rid="t2-copd-11-2543"><offsets xml_i="16967" xml_f="16974" txt_i="10425" txt_f="10432">Table 2</offsets></xref><offsets xml_i="16981" xml_f="17510" txt_i="10432" txt_f="10958">). COPD exacerbations were found to be the frequent AEs in all treatment groups, with their lowest occurrence in patients treated with IND/GLY (~12%). Serious AEs were comparable across all treatment groups. Moreover, no cardiovascular AEs, major adverse cardiac events, cerebro–cardiovascular AEs, abnormal changes from baseline QTc in resting ECG was obtained using Bazett’s formula (QTcB), Fridericia’s formula (QTcF) (&lt;10 mlliseconds) or heart rate, or imbalance in hematocrit values was observed in the Japanese subgroup.</offsets></p></sec></sec><sec sec-type="discussion"><title><offsets xml_i="17560" xml_f="17570" txt_i="10961" txt_f="10971">Discussion</offsets></title><p><offsets xml_i="17581" xml_f="17847" txt_i="10972" txt_f="11238">The aim of this post hoc analysis was to explore the efficacy and safety profile of IND/GLY in the Japanese subgroup of the SHINE study. Based on the overall results of the SHINE study, the efficacy of IND/GLY was superior to that of placebo, with comparable safety.</offsets><xref rid="b10-copd-11-2543" ref-type="bibr"><offsets xml_i="17892" xml_f="17894" txt_i="11238" txt_f="11240">10</offsets></xref><offsets xml_i="17901" xml_f="18390" txt_i="11240" txt_f="11729"> The results of this analysis support our claim that IND/GLY improves lung function and health status in patients with moderate-to-severe COPD with compromised airflow according to the GOLD guidelines, irrespective of ethnicity. The fourth edition of the JRS guidelines, which is customized for the Japanese scenario, recommend LAMA/LABA for the management of moderate-to-severe COPD with symptoms and the use of ICS in combination with LABA or LAMA only if the condition does not improve.</offsets><xref rid="b4-copd-11-2543" ref-type="bibr"><offsets xml_i="18434" xml_f="18435" txt_i="11729" txt_f="11730">4</offsets></xref><offsets xml_i="18442" xml_f="18443" txt_i="11730" txt_f="11731">,</offsets><xref rid="b5-copd-11-2543" ref-type="bibr"><offsets xml_i="18487" xml_f="18488" txt_i="11731" txt_f="11732">5</offsets></xref><offsets xml_i="18495" xml_f="18496" txt_i="11732" txt_f="11733">,</offsets><xref rid="b12-copd-11-2543" ref-type="bibr"><offsets xml_i="18541" xml_f="18543" txt_i="11733" txt_f="11735">12</offsets></xref><offsets xml_i="18550" xml_f="18742" txt_i="11735" txt_f="11927"> GOLD strategy that considers diverse ethnicity as well as various COPD phenotypes differs from the JRS guidelines, which are specific for the Japanese population, in terms of prescribing ICS.</offsets><xref rid="b4-copd-11-2543" ref-type="bibr"><offsets xml_i="18786" xml_f="18787" txt_i="11927" txt_f="11928">4</offsets></xref><offsets xml_i="18794" xml_f="18795" txt_i="11928" txt_f="11929">,</offsets><xref rid="b5-copd-11-2543" ref-type="bibr"><offsets xml_i="18839" xml_f="18840" txt_i="11929" txt_f="11930">5</offsets></xref><offsets xml_i="18847" xml_f="19001" txt_i="11930" txt_f="12084"> The difference in the recommendations may be due to the fact that Japanese patients with COPD experience fewer COPD exacerbations compared to Caucasians.</offsets><xref rid="b12-copd-11-2543" ref-type="bibr"><offsets xml_i="19046" xml_f="19048" txt_i="12084" txt_f="12086">12</offsets></xref><offsets xml_i="19055" xml_f="19383" txt_i="12086" txt_f="12414"> In the Japanese subgroup of the SHINE study, we observed greater improvements in lung function with IND/GLY versus IND, GLY, and TIO mono-therapies, although the improvement in quality of life was comparable across all groups. The results of this subgroup analysis were similar to those observed in the entire study population.</offsets><xref rid="b10-copd-11-2543" ref-type="bibr"><offsets xml_i="19428" xml_f="19430" txt_i="12414" txt_f="12416">10</offsets></xref><offsets xml_i="19437" xml_f="19509" txt_i="12416" txt_f="12488"> The small sample size is perhaps responsible for the lower baseline FEV</offsets><sub><offsets xml_i="19514" xml_f="19515" txt_i="12488" txt_f="12489">1</offsets></sub><offsets xml_i="19521" xml_f="19731" txt_i="12489" txt_f="12699"> observed in the TIO group (1.22 L) than the IND/GLY group (1.36 L), which was at least partially responsible for the 90 mL “treatment effect” of IND/GLY versus TIO at the end of 26 weeks. However, baseline FEV</offsets><sub><offsets xml_i="19736" xml_f="19737" txt_i="12699" txt_f="12700">1</offsets></sub><offsets xml_i="19743" xml_f="19880" txt_i="12700" txt_f="12837"> was used as a covariate in the statistical analysis, and the treatment effect was adjusted to account for the baseline difference in FEV</offsets><sub><offsets xml_i="19885" xml_f="19886" txt_i="12837" txt_f="12838">1</offsets></sub><offsets xml_i="19892" xml_f="20026" txt_i="12838" txt_f="12972"> between the IND/GLY and TIO groups. The aforementioned findings were similar to those reported in another study, wherein baseline FEV</offsets><sub><offsets xml_i="20031" xml_f="20032" txt_i="12972" txt_f="12973">1</offsets></sub><offsets xml_i="20038" xml_f="20139" txt_i="12973" txt_f="13074"> affected the treatment efficacy of a bronchodilator, which showed a smaller change from baseline FEV</offsets><sub><offsets xml_i="20144" xml_f="20145" txt_i="13074" txt_f="13075">1</offsets></sub><offsets xml_i="20151" xml_f="20193" txt_i="13075" txt_f="13117"> value in patients with lower baseline FEV</offsets><sub><offsets xml_i="20198" xml_f="20199" txt_i="13117" txt_f="13118">1</offsets></sub><offsets xml_i="20205" xml_f="20206" txt_i="13118" txt_f="13119">.</offsets><xref rid="b13-copd-11-2543" ref-type="bibr"><offsets xml_i="20251" xml_f="20253" txt_i="13119" txt_f="13121">13</offsets></xref><offsets xml_i="20260" xml_f="20315" txt_i="13121" txt_f="13176"> In addition to the observed improvements in trough FEV</offsets><sub><offsets xml_i="20320" xml_f="20321" txt_i="13176" txt_f="13177">1</offsets></sub><offsets xml_i="20327" xml_f="20407" txt_i="13177" txt_f="13257">, our study also demonstrated rapid bronchodilation with IND/GLY in terms of FEV</offsets><sub><offsets xml_i="20412" xml_f="20413" txt_i="13257" txt_f="13258">1</offsets></sub><offsets xml_i="20419" xml_f="20423" txt_i="13258" txt_f="13262"> AUC</offsets><sub><offsets xml_i="20428" xml_f="20437" txt_i="13262" txt_f="13271">5 min–4 h</offsets></sub><offsets xml_i="20443" xml_f="20859" txt_i="13271" txt_f="13687"> compared to the monotherapy components, TIO, and placebo. In previous studies, spirometric outcomes of IND/GLY treatment showed a comparable reduction in the rate of COPD exacerbations, along with superior improvement in lung function versus its monotherapy components, TIO, and salmeterol/fluticasone and without considerable variations in the TDI focal score and SGRQ total score among different treatment groups.</offsets><xref rid="b9-copd-11-2543" ref-type="bibr"><offsets xml_i="20903" xml_f="20904" txt_i="13687" txt_f="13688">9</offsets></xref><offsets xml_i="20911" xml_f="20912" txt_i="13688" txt_f="13689">,</offsets><xref rid="b11-copd-11-2543" ref-type="bibr"><offsets xml_i="20957" xml_f="20959" txt_i="13689" txt_f="13691">11</offsets></xref><offsets xml_i="20966" xml_f="20967" txt_i="13691" txt_f="13692">,</offsets><xref rid="b14-copd-11-2543" ref-type="bibr"><offsets xml_i="21012" xml_f="21014" txt_i="13692" txt_f="13694">14</offsets></xref><offsets xml_i="21021" xml_f="21022" txt_i="13694" txt_f="13695">,</offsets><xref rid="b15-copd-11-2543" ref-type="bibr"><offsets xml_i="21067" xml_f="21069" txt_i="13695" txt_f="13697">15</offsets></xref><offsets xml_i="21076" xml_f="21270" txt_i="13697" txt_f="13891"> In our study, the results of the Japanese subgroup analysis showed comparable improvements in the TDI focal score and SGRQ total score, which is consistent with the results of a previous study.</offsets><xref rid="b14-copd-11-2543" ref-type="bibr"><offsets xml_i="21315" xml_f="21317" txt_i="13891" txt_f="13893">14</offsets></xref><offsets xml_i="21324" xml_f="21642" txt_i="13893" txt_f="14211"> A higher proportion of patients from the IND/GLY group achieved minimal clinically important differences for TDI and SGRQ compared with the other treatment groups. Moreover, the number of patients in the Japanese subgroup was small to determine the significant improvement in the TDI focal score and SGRQ total score.</offsets></p><p><offsets xml_i="21649" xml_f="21789" txt_i="14212" txt_f="14352">The SHINE study demonstrated that safety profile of IND/GLY in Japanese patients with COPD was consistent with the overall study population.</offsets><xref rid="b10-copd-11-2543" ref-type="bibr"><offsets xml_i="21834" xml_f="21836" txt_i="14352" txt_f="14354">10</offsets></xref><offsets xml_i="21843" xml_f="22408" txt_i="14354" txt_f="14919"> The most frequently reported AE was COPD exacerbation in the Japanese subgroup, and the occurrence was ~12%, which was lower compared with TIO (25%) and placebo (~32%). Furthermore, the incidents of exacerbations were lesser in the Japanese subgroup than the overall study population, where ~39% exacerbations were reported. This fact was supported by the results of a previous study that demonstrated that IND/GLY was superior in preventing moderate-to-severe COPD exacerbations compared with TIO, with concomitant improvements in lung function and health status.</offsets><xref rid="b9-copd-11-2543" ref-type="bibr"><offsets xml_i="22452" xml_f="22453" txt_i="14919" txt_f="14920">9</offsets></xref><offsets xml_i="22460" xml_f="22715" txt_i="14920" txt_f="15175"> A pooled analysis of 14 randomized clinical trials with data from 11,404 patients with COPD demonstrated that IND/GLY did not increase the risk of investigated safety end points and had a comparable safety profile as its monocomponents, TIO, and placebo.</offsets><xref rid="b16-copd-11-2543" ref-type="bibr"><offsets xml_i="22760" xml_f="22762" txt_i="15175" txt_f="15177">16</offsets></xref></p></sec><sec><title><offsets xml_i="22791" xml_f="22801" txt_i="15179" txt_f="15189">Conclusion</offsets></title><p><offsets xml_i="22812" xml_f="23139" txt_i="15190" txt_f="15517">Based on the results of this subgroup analysis, we can conclude that the efficacy and safety of IND/GLY in the Japanese population were similar to that in the overall study population of the SHINE study; thus, IND/GLY may be considered as a treatment option for the management of Japanese patients with moderate-to-severe COPD.</offsets></p></sec><sec sec-type="supplementary-material"><title><offsets xml_i="23195" xml_f="23217" txt_i="15519" txt_f="15541">Supplementary material</offsets></title><supplementary-material content-type="local-data" id="SD1-copd-11-2543"><table-wrap id="ts1-copd-11-2543" position="float"><label><offsets xml_i="23355" xml_f="23363" txt_i="15542" txt_f="15550">Table S1</offsets></label><caption><p><offsets xml_i="23383" xml_f="23439" txt_i="15550" txt_f="15606">List of relevant national and local ethics review boards</offsets></p></caption><table frame="hsides" rules="groups"><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="23555" xml_f="23559" txt_i="15607" txt_f="15611">  1.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="23618" xml_f="23661" txt_i="15612" txt_f="15655">United States: Food and Drug Administration</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="23729" xml_f="23733" txt_i="15656" txt_f="15660">  2.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="23792" xml_f="23872" txt_i="15661" txt_f="15741">Argentina: Administracion Nacional de Medicamentos, Alimentos y TecnologiaMedica</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="23940" xml_f="23944" txt_i="15742" txt_f="15746">  3.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="24003" xml_f="24048" txt_i="15747" txt_f="15792">Argentina: Human Research Bioethics Committee</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="24116" xml_f="24120" txt_i="15793" txt_f="15797">  4.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="24179" xml_f="24208" txt_i="15798" txt_f="15827">Argentina: Ministry of Health</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="24276" xml_f="24280" txt_i="15828" txt_f="15832">  5.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="24339" xml_f="24414" txt_i="15833" txt_f="15908">Australia: Department of Health and Ageing Therapeutic Goods Administration</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="24482" xml_f="24486" txt_i="15909" txt_f="15913">  6.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="24545" xml_f="24587" txt_i="15914" txt_f="15956">Australia: Human Research Ethics Committee</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="24655" xml_f="24659" txt_i="15957" txt_f="15961">  7.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="24718" xml_f="24773" txt_i="15962" txt_f="16017">Australia: National Health and Medical Research Council</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="24841" xml_f="24845" txt_i="16018" txt_f="16022">  8.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="24904" xml_f="24935" txt_i="16023" txt_f="16054">Bulgaria: Bulgarian Drug Agency</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="25003" xml_f="25007" txt_i="16055" txt_f="16059">  9.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="25066" xml_f="25094" txt_i="16060" txt_f="16088">Bulgaria: Ministry of Health</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="25162" xml_f="25165" txt_i="16089" txt_f="16092">10.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="25224" xml_f="25245" txt_i="16093" txt_f="16114">Canada: Health Canada</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="25313" xml_f="25316" txt_i="16115" txt_f="16118">11.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="25375" xml_f="25410" txt_i="16119" txt_f="16154">China: Food and Drug Administration</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="25478" xml_f="25481" txt_i="16155" txt_f="16158">12.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="25540" xml_f="25565" txt_i="16159" txt_f="16184">Finland: Ethics Committee</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="25633" xml_f="25636" txt_i="16185" txt_f="16188">13.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="25695" xml_f="25741" txt_i="16189" txt_f="16235">Finland: Ministry of Social Affairs and Health</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="25809" xml_f="25812" txt_i="16236" txt_f="16239">14.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="25871" xml_f="25904" txt_i="16240" txt_f="16273">Finland: Finnish Medicines Agency</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="25972" xml_f="25975" txt_i="16274" txt_f="16277">15.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="26034" xml_f="26125" txt_i="16278" txt_f="16369">France: Afssaps - Agencefrançaise de sécurité sanitaire des produits de santé (Saint-Denis)</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="26193" xml_f="26196" txt_i="16370" txt_f="16373">16.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="26255" xml_f="26293" txt_i="16374" txt_f="16412">France: Direction Générale de la Santé</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="26361" xml_f="26364" txt_i="16413" txt_f="16416">17.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="26423" xml_f="26463" txt_i="16417" txt_f="16457">France: French Data Protection Authority</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="26531" xml_f="26534" txt_i="16458" txt_f="16461">18.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="26593" xml_f="26648" txt_i="16462" txt_f="16517">France: Haute Autorité de Santé Transparency Commission</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="26716" xml_f="26719" txt_i="16518" txt_f="16521">19.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="26778" xml_f="26817" txt_i="16522" txt_f="16561">France: Institutional Ethical Committee</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="26885" xml_f="26888" txt_i="16562" txt_f="16565">20.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="26947" xml_f="26973" txt_i="16566" txt_f="16592">France: Ministry of Health</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="27041" xml_f="27044" txt_i="16593" txt_f="16596">21.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="27103" xml_f="27178" txt_i="16597" txt_f="16672">France: National Consultative Ethics Committee for Health and Life Sciences</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="27246" xml_f="27249" txt_i="16673" txt_f="16676">22.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="27308" xml_f="27334" txt_i="16677" txt_f="16703">Germany: Ethics Commission</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="27402" xml_f="27405" txt_i="16704" txt_f="16707">23.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="27464" xml_f="27520" txt_i="16708" txt_f="16764">Germany: Federal Institute for Drugs and Medical Devices</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="27588" xml_f="27591" txt_i="16765" txt_f="16768">24.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="27650" xml_f="27701" txt_i="16769" txt_f="16820">Germany: Federal Ministry of Education and Research</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="27769" xml_f="27772" txt_i="16821" txt_f="16824">25.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="27831" xml_f="27901" txt_i="16825" txt_f="16895">Germany: Federal Ministry of Food, Agriculture and Consumer Protection</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="27969" xml_f="27972" txt_i="16896" txt_f="16899">26.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="28031" xml_f="28097" txt_i="16900" txt_f="16966">Germany: German Institute of Medical Documentation and Information</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="28165" xml_f="28168" txt_i="16967" txt_f="16970">27.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="28227" xml_f="28254" txt_i="16971" txt_f="16998">Germany: Ministry of Health</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="28322" xml_f="28325" txt_i="16999" txt_f="17002">28.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="28384" xml_f="28414" txt_i="17003" txt_f="17033">Germany: Paul-Ehrlich-Institut</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="28482" xml_f="28485" txt_i="17034" txt_f="17037">29.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="28544" xml_f="28649" txt_i="17038" txt_f="17143">Guatemala: MSPAS - Ministerio de SaludPública y Asistencia Social: Programa Nacional de Farmacovigilancia</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="28717" xml_f="28720" txt_i="17144" txt_f="17147">30.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="28779" xml_f="28821" txt_i="17148" txt_f="17190">Hungary: Research Ethics Medical Committee</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="28889" xml_f="28892" txt_i="17191" txt_f="17194">31.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="28951" xml_f="28990" txt_i="17195" txt_f="17234">Hungary: National Institute of Pharmacy</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="29058" xml_f="29061" txt_i="17235" txt_f="17238">32.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="29120" xml_f="29170" txt_i="17239" txt_f="17289">India: Central Drugs Standard Control Organization</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="29238" xml_f="29241" txt_i="17290" txt_f="17293">33.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="29300" xml_f="29334" txt_i="17294" txt_f="17328">India: Department of Atomic Energy</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="29402" xml_f="29405" txt_i="17329" txt_f="17332">34.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="29464" xml_f="29504" txt_i="17333" txt_f="17373">India: Drugs Controller General of India</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="29572" xml_f="29575" txt_i="17374" txt_f="17377">35.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="29634" xml_f="29675" txt_i="17378" txt_f="17419">India: Indian Council of Medical Research</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="29743" xml_f="29746" txt_i="17420" txt_f="17423">36.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="29805" xml_f="29838" txt_i="17424" txt_f="17457">India: Institutional Review Board</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="29906" xml_f="29909" txt_i="17458" txt_f="17461">37.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="29968" xml_f="29993" txt_i="17462" txt_f="17487">India: Ministry of Health</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="30061" xml_f="30064" txt_i="17488" txt_f="17491">38.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="30123" xml_f="30164" txt_i="17492" txt_f="17533">India: Ministry of Science and Technology</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="30232" xml_f="30235" txt_i="17534" txt_f="17537">39.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="30294" xml_f="30341" txt_i="17538" txt_f="17585">India: Science and Engineering Research Council</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="30409" xml_f="30412" txt_i="17586" txt_f="17589">40.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="30471" xml_f="30515" txt_i="17590" txt_f="17634">Japan: Ministry of Health, Labor and Welfare</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="30583" xml_f="30586" txt_i="17635" txt_f="17638">41.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="30645" xml_f="30669" txt_i="17639" txt_f="17663">Mexico: Ethics Committee</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="30737" xml_f="30740" txt_i="17664" txt_f="17667">42.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="30799" xml_f="30861" txt_i="17668" txt_f="17730">Mexico: Federal Commission for Protection Against Health Risks</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="30929" xml_f="30932" txt_i="17731" txt_f="17734">43.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="30991" xml_f="31047" txt_i="17735" txt_f="17791">Mexico: Federal Commission for Sanitary Risks Protection</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="31115" xml_f="31118" txt_i="17792" txt_f="17795">44.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="31177" xml_f="31203" txt_i="17796" txt_f="17822">Mexico: Ministry of Health</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="31271" xml_f="31274" txt_i="17823" txt_f="17826">45.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="31333" xml_f="31383" txt_i="17827" txt_f="17877">Mexico: National Council of Science and Technology</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="31451" xml_f="31454" txt_i="17878" txt_f="17881">46.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="31513" xml_f="31576" txt_i="17882" txt_f="17945">Mexico: National Institute of Public Health, Health Secretariat</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="31644" xml_f="31647" txt_i="17946" txt_f="17949">47.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="31706" xml_f="31751" txt_i="17950" txt_f="17995">The Netherlands: Independent Ethics Committee</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="31819" xml_f="31822" txt_i="17996" txt_f="17999">48.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="31881" xml_f="31928" txt_i="18000" txt_f="18047">The Netherlands: Dutch Health Care Inspectorate</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="31996" xml_f="31999" txt_i="18048" txt_f="18051">49.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="32058" xml_f="32113" txt_i="18052" txt_f="18107">The Netherlands: Medical Ethics Review Committee (METC)</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="32181" xml_f="32184" txt_i="18108" txt_f="18111">50.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="32243" xml_f="32292" txt_i="18112" txt_f="18161">The Netherlands: Medicines Evaluation Board (MEB)</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="32360" xml_f="32363" txt_i="18162" txt_f="18165">51.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="32422" xml_f="32504" txt_i="18166" txt_f="18248">The Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="32572" xml_f="32575" txt_i="18249" txt_f="18252">52.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="32634" xml_f="32660" txt_i="18253" txt_f="18279">Panama: Ministry of Health</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="32728" xml_f="32731" txt_i="18280" txt_f="18283">53.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="32790" xml_f="32823" txt_i="18284" txt_f="18317">Philippines: Department of Health</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="32891" xml_f="32894" txt_i="18318" txt_f="18321">54.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="32953" xml_f="32990" txt_i="18322" txt_f="18359">Philippines: Bureau of Food and Drugs</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="33058" xml_f="33061" txt_i="18360" txt_f="18363">55.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="33120" xml_f="33212" txt_i="18364" txt_f="18456">Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="33280" xml_f="33283" txt_i="18457" txt_f="18460">56.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="33342" xml_f="33368" txt_i="18461" txt_f="18487">Poland: Ministry of Health</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="33436" xml_f="33439" txt_i="18488" txt_f="18491">57.</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="33498" xml_f="33546" txt_i="18492" txt_f="18540">Poland: Ministry of Science and Higher Education</offsets></td></tr></tbody></table></table-wrap></supplementary-material></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to thank their colleagues who were involved in the planning, execution, and analysis of the SHINE study and all the study participants. This study was sponsored by Novartis Pharma AG, Basel, Switzerland. The authors were assisted in the preparation of this manuscript by Kevin Roche and Santanu Bhadra of Novartis Healthcare Pvt. Ltd., Hyderabad, India.</p></ack><fn-group><fn><p><bold>Author contributions</bold></p><p>All authors contributed toward data analysis, drafting and critically revising the paper and agree to be accountable for all aspects of the work.</p></fn><fn fn-type="COI-statement"><p><bold>Disclosure</bold></p><p>SH had received grants and/or lecture fees from Astellas Pharma Inc., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., GlaxoSmithKline K.K., KYORIN Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co. Ltd., Torii Pharmaceutical Co. Ltd., and Novartis Pharma K.K. within the last 3 years. SM, TK, KI, and DB are employees of the study sponsor Novartis. The authors report no other conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-copd-11-2543"><label>1</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Vital Statistics, Ministry of Health, Labor Welfare Japan</collab></person-group><year>2014</year><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.mhlw.go.jp/english/new-info/">http://www.mhlw.go.jp/english/new-info/</ext-link></comment><date-in-citation>Accessed December 12, 2015</date-in-citation></element-citation></ref><ref id="b2-copd-11-2543"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukuchi</surname><given-names>Y</given-names></name><name><surname>Fernandez</surname><given-names>L</given-names></name><name><surname>Kuo</surname><given-names>HP</given-names></name><etal></etal></person-group><article-title>Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial</article-title><source>Respirology</source><year>2011</year><volume>16</volume><issue>5</issue><fpage>825</fpage><lpage>835</lpage><pub-id pub-id-type="pmid">21539680</pub-id></element-citation></ref><ref id="b3-copd-11-2543"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishikawa</surname><given-names>N</given-names></name><name><surname>Hattori</surname><given-names>N</given-names></name><name><surname>Kohno</surname><given-names>N</given-names></name><name><surname>Kobayashi</surname><given-names>A</given-names></name><name><surname>Hayamizu</surname><given-names>T</given-names></name><name><surname>Johnson</surname><given-names>M</given-names></name></person-group><article-title>Airway inflammation in Japanese COPD patients compared with smoking and nonsmoking controls</article-title><source>Int J Chron Obstruct Pulmon Dis</source><year>2015</year><volume>10</volume><fpage>185</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">25670894</pub-id></element-citation></ref><ref id="b4-copd-11-2543"><label>4</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease</collab></person-group><source>Global Initiative for Chronic Obstructive Lung Disease (GOLD 2016)</source><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.goldcopd.com">http://www.goldcopd.com</ext-link></comment><date-in-citation>Accessed January 6, 2016</date-in-citation></element-citation></ref><ref id="b5-copd-11-2543"><label>5</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Japanese Respiratory Society</collab></person-group><source>Guidelines for the Diagnosis and Treatment of COPD</source><edition>4th edition</edition><publisher-name>Japanese Respiratory Society</publisher-name><year>2013</year><comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://www.jrs.or.jp/modules/guidelines/index.php?content_id=1">https://www.jrs.or.jp/modules/guidelines/index.php?content_id=1</ext-link></comment><date-in-citation>Accessed December 12, 2015</date-in-citation></element-citation></ref><ref id="b6-copd-11-2543"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beeh</surname><given-names>KM</given-names></name><name><surname>Korn</surname><given-names>S</given-names></name><name><surname>Beier</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study</article-title><source>Respir Med</source><year>2014</year><volume>108</volume><issue>4</issue><fpage>584</fpage><lpage>592</lpage><pub-id pub-id-type="pmid">24534204</pub-id></element-citation></ref><ref id="b7-copd-11-2543"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahl</surname><given-names>R</given-names></name><name><surname>Chapman</surname><given-names>KR</given-names></name><name><surname>Rudolf</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study</article-title><source>Respir Med</source><year>2013</year><volume>107</volume><issue>10</issue><fpage>1558</fpage><lpage>1567</lpage><pub-id pub-id-type="pmid">23867808</pub-id></element-citation></ref><ref id="b8-copd-11-2543"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahler</surname><given-names>DA</given-names></name><name><surname>Decramer</surname><given-names>M</given-names></name><name><surname>D’Urzo</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study</article-title><source>Eur Respir J</source><year>2014</year><volume>43</volume><issue>6</issue><fpage>1599</fpage><lpage>1609</lpage><pub-id pub-id-type="pmid">24176997</pub-id></element-citation></ref><ref id="b9-copd-11-2543"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wedzicha</surname><given-names>JA</given-names></name><name><surname>Decramer</surname><given-names>M</given-names></name><name><surname>Ficker</surname><given-names>JH</given-names></name><etal></etal></person-group><article-title>Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study</article-title><source>Lancet Respir Med</source><year>2013</year><volume>1</volume><issue>3</issue><fpage>199</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">24429126</pub-id></element-citation></ref><ref id="b10-copd-11-2543"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bateman</surname><given-names>ED</given-names></name><name><surname>Ferguson</surname><given-names>GT</given-names></name><name><surname>Barnes</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study</article-title><source>Eur Respir J</source><year>2013</year><volume>42</volume><issue>6</issue><fpage>1484</fpage><lpage>1494</lpage><pub-id pub-id-type="pmid">23722616</pub-id></element-citation></ref><ref id="b11-copd-11-2543"><label>11</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Asai</surname><given-names>K</given-names></name><name><surname>Minakata</surname><given-names>Y</given-names></name><name><surname>Hirata</surname><given-names>K</given-names></name><etal></etal></person-group><source>QVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: The ARISE study</source><conf-name>European Respiratory Society Annual Congress 2013</conf-name><conf-loc>Barcelona, Spain</conf-loc><year>2013</year><fpage>P3392</fpage></element-citation></ref><ref id="b12-copd-11-2543"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horita</surname><given-names>N</given-names></name><name><surname>Kaneko</surname><given-names>T</given-names></name></person-group><article-title>Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan</article-title><source>Int J Chron Obstruct Pulmon Dis</source><year>2015</year><volume>10</volume><fpage>813</fpage><lpage>822</lpage><pub-id pub-id-type="pmid">25960646</pub-id></element-citation></ref><ref id="b13-copd-11-2543"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calverley</surname><given-names>P</given-names></name><name><surname>Pauwels</surname><given-names>RA</given-names></name><name><surname>Jones</surname><given-names>PW</given-names></name><name><surname>Anderson</surname><given-names>JA</given-names></name><name><surname>Vestbos</surname><given-names>J</given-names></name></person-group><article-title>The severity of airways obstruction as a determinant of treatment response in COPD</article-title><source>Int J Chron Obstruct Pulmon Dis</source><year>2006</year><volume>1</volume><issue>3</issue><fpage>209</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">18046858</pub-id></element-citation></ref><ref id="b14-copd-11-2543"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogelmeier</surname><given-names>CF</given-names></name><name><surname>Bateman</surname><given-names>ED</given-names></name><name><surname>Pallante</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study</article-title><source>Lancet Respir Med</source><year>2013</year><volume>1</volume><issue>1</issue><fpage>51</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">24321804</pub-id></element-citation></ref><ref id="b15-copd-11-2543"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><etal></etal><collab>LANTERN Investigators</collab></person-group><article-title>LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD</article-title><source>Int J Chron Obstruct Pulmon Dis</source><year>2015</year><volume>10</volume><fpage>1015</fpage><lpage>1026</lpage><pub-id pub-id-type="pmid">26082625</pub-id></element-citation></ref><ref id="b16-copd-11-2543"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wedzicha</surname><given-names>JA</given-names></name><name><surname>Dahl</surname><given-names>R</given-names></name><name><surname>Buhl</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients</article-title><source>Respir Med</source><year>2014</year><volume>108</volume><issue>10</issue><fpage>1498</fpage><lpage>1507</lpage><pub-id pub-id-type="pmid">25135743</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-copd-11-2543" position="float"><label>Figure 1</label><caption><p>Patient disposition.</p><p><bold>Note:</bold> n, number of patients.</p><p><bold>Abbreviations:</bold> IND, indacaterol; GLY, glycopyrronium; od, once daily; TIO, tiotropium; ol, open label.</p></caption><graphic xlink:href="copd-11-2543Fig1"></graphic></fig><fig id="f2-copd-11-2543" position="float"><label>Figure 2</label><caption><p>Trough FEV<sub>1</sub> (L) after 26 weeks in the Japanese subgroup.</p><p><bold>Notes:</bold> Data are presented as LSM (standard error). Trough FEV<sub>1</sub> is defined as the average of the post dose 23 hours 15 minutes and 23 hours 45 minutes FEV<sub>1</sub> values (excluding values taken outside 22 hours 45 minutes and 24 hours 15 minutes post dose) at Day 2.</p><p><bold>Abbreviations:</bold> FEV<sub>1</sub>, forced expiratory volume in 1 second; LSM, least-squares mean; IND, indacaterol; GLY, glycopyrronium; od, once daily; TIO, tiotropium; ∆, treatment difference.</p></caption><graphic xlink:href="copd-11-2543Fig2"></graphic></fig><fig id="f3-copd-11-2543" position="float"><label>Figure 3</label><caption><p>Trough FEV<sub>1</sub> (L) over 26 weeks in the Japanese subgroup.</p><p><bold>Note:</bold> Data are presented as LSM (standard error).</p><p><bold>Abbreviations:</bold> FEV<sub>1</sub>, forced expiratory volume in 1 second; LSM, least-squares mean; IND, indacaterol; GLY, glycopyrronium; od, once daily; TIO, tiotropium.</p></caption><graphic xlink:href="copd-11-2543Fig3"></graphic></fig><fig id="f4-copd-11-2543" position="float"><label>Figure 4</label><caption><p>Peak FEV<sub>1</sub> (L) from 5 minutes to 4 hours at Week 26 in the Japanese subgroup.</p><p><bold>Notes:</bold> Data are presented as LSM (standard error). Peak FEV<sub>1</sub> is defined as the maximum FEV<sub>1</sub> during the first 4 hours after dosing.</p><p><bold>Abbreviations:</bold> FEV<sub>1</sub>, forced expiratory volume in 1 second; LSM, least-squares mean; IND, indacaterol; GLY, glycopyrronium; od, once daily; TIO, tiotropium; ∆, treatment difference.</p></caption><graphic xlink:href="copd-11-2543Fig4"></graphic></fig><fig id="f5-copd-11-2543" position="float"><label>Figure 5</label><caption><p>FEV<sub>1</sub> AUC<sub>5 min–4 h</sub> (L) at Week 26 in the Japanese subgroup.</p><p><bold>Note:</bold> Data are presented as LSM (standard error).</p><p><bold>Abbreviations:</bold> FEV<sub>1</sub> AUC<sub>5 min-4 h</sub>, area under the curve for FEV<sub>1</sub> from 5 minutes to 4 hours; FEV<sub>1</sub>, forced expiratory volume in 1 second; LSM, least-squares mean; IND, indacaterol; GLY, glycopyrronium; od, once daily; TIO, tiotropium; ∆, treatment difference.</p></caption><graphic xlink:href="copd-11-2543Fig5"></graphic></fig><table-wrap id="t1-copd-11-2543" position="float"><label>Table 1</label><caption><p>Demographic and baseline clinical characteristics of the Japanese subgroup</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"></th><th valign="top" align="left" rowspan="1" colspan="1">IND/GLY (n=42)</th><th valign="top" align="left" rowspan="1" colspan="1">IND (n=41)</th><th valign="top" align="left" rowspan="1" colspan="1">GLY (n=40)</th><th valign="top" align="left" rowspan="1" colspan="1">TIO<xref ref-type="table-fn" rid="tfn2-copd-11-2543">*</xref> (n=40)</th><th valign="top" align="left" rowspan="1" colspan="1">Placebo (n=19)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age, years</td><td valign="top" align="left" rowspan="1" colspan="1">71.0 (6.92)</td><td valign="top" align="left" rowspan="1" colspan="1">69.2 (5.96)</td><td valign="top" align="left" rowspan="1" colspan="1">69.0 (8.87)</td><td valign="top" align="left" rowspan="1" colspan="1">67.8 (9.25)</td><td valign="top" align="left" rowspan="1" colspan="1">68.9 (5.22)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sex, male, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">42 (100)</td><td valign="top" align="left" rowspan="1" colspan="1">40 (97.6)</td><td valign="top" align="left" rowspan="1" colspan="1">38 (95.0)</td><td valign="top" align="left" rowspan="1" colspan="1">37 (92.5)</td><td valign="top" align="left" rowspan="1" colspan="1">18 (94.7)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Body mass index, kg/m<sup>2</sup></td><td valign="top" align="left" rowspan="1" colspan="1">22.4 (3.35)</td><td valign="top" align="left" rowspan="1" colspan="1">22.7 (3.17)</td><td valign="top" align="left" rowspan="1" colspan="1">22.2 (3.05)</td><td valign="top" align="left" rowspan="1" colspan="1">22.8 (3.54)</td><td valign="top" align="left" rowspan="1" colspan="1">24.3 (1.86)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Smoking history, pack-years</td><td valign="top" align="left" rowspan="1" colspan="1">64.7 (25.21)</td><td valign="top" align="left" rowspan="1" colspan="1">59.9 (27.71)</td><td valign="top" align="left" rowspan="1" colspan="1">69.8 (33.36)</td><td valign="top" align="left" rowspan="1" colspan="1">64.7 (38.25)</td><td valign="top" align="left" rowspan="1" colspan="1">52.3 (20.20)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Smoking status, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Ex-smoker</td><td valign="top" align="left" rowspan="1" colspan="1">31 (73.8)</td><td valign="top" align="left" rowspan="1" colspan="1">31 (75.6)</td><td valign="top" align="left" rowspan="1" colspan="1">31 (77.5)</td><td valign="top" align="left" rowspan="1" colspan="1">29 (72.5)</td><td valign="top" align="left" rowspan="1" colspan="1">17 (89.5)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Current smoker</td><td valign="top" align="left" rowspan="1" colspan="1">11 (26.2)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (24.4)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (22.5)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (27.5)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (10.5)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ICS use at baseline, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> No</td><td valign="top" align="left" rowspan="1" colspan="1">31 (73.8)</td><td valign="top" align="left" rowspan="1" colspan="1">30 (73.2)</td><td valign="top" align="left" rowspan="1" colspan="1">28 (70.0)</td><td valign="top" align="left" rowspan="1" colspan="1">29 (72.5)</td><td valign="top" align="left" rowspan="1" colspan="1">14 (73.7)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Yes</td><td valign="top" align="left" rowspan="1" colspan="1">11 (26.2)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (26.8)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (30.0)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (27.5)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (26.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Number of COPD exacerbations in the previous year, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> 0</td><td valign="top" align="left" rowspan="1" colspan="1">39 (92.9)</td><td valign="top" align="left" rowspan="1" colspan="1">32 (78.0)</td><td valign="top" align="left" rowspan="1" colspan="1">31 (77.5)</td><td valign="top" align="left" rowspan="1" colspan="1">33 (82.5)</td><td valign="top" align="left" rowspan="1" colspan="1">17 (89.5)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> 1</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4.8)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (22.0)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (20.0)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (17.5)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (5.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> ≥2</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2.4)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2.5)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">1 (5.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Severity of COPD (GOLD 2008), n (%)</td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Moderate COPD</td><td valign="top" align="left" rowspan="1" colspan="1">32 (76.2)</td><td valign="top" align="left" rowspan="1" colspan="1">31 (75.6)</td><td valign="top" align="left" rowspan="1" colspan="1">35 (87.5)</td><td valign="top" align="left" rowspan="1" colspan="1">28 (70.0)</td><td valign="top" align="left" rowspan="1" colspan="1">14 (73.7)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Severe COPD</td><td valign="top" align="left" rowspan="1" colspan="1">10 (23.8)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (24.4)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (10.0)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (30.0)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (26.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Duration of COPD, years</td><td valign="top" align="left" rowspan="1" colspan="1">3.6 (3.23)</td><td valign="top" align="left" rowspan="1" colspan="1">3.9 (5.01)</td><td valign="top" align="left" rowspan="1" colspan="1">4.0 (3.80)</td><td valign="top" align="left" rowspan="1" colspan="1">3.4 (2.10)</td><td valign="top" align="left" rowspan="1" colspan="1">3.2 (2.78)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FEV<sub>1</sub>, prebronchodilator, L</td><td valign="top" align="left" rowspan="1" colspan="1">1.36 (0.44)</td><td valign="top" align="left" rowspan="1" colspan="1">1.32 (0.43)</td><td valign="top" align="left" rowspan="1" colspan="1">1.35 (0.41)</td><td valign="top" align="left" rowspan="1" colspan="1">1.22 (0.42)</td><td valign="top" align="left" rowspan="1" colspan="1">1.27 (0.38)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FEV<sub>1</sub>, postbronchodilator, L</td><td valign="top" align="left" rowspan="1" colspan="1">1.60 (0.42)</td><td valign="top" align="left" rowspan="1" colspan="1">1.54 (0.46)</td><td valign="top" align="left" rowspan="1" colspan="1">1.56 (0.42)</td><td valign="top" align="left" rowspan="1" colspan="1">1.48 (0.45)</td><td valign="top" align="left" rowspan="1" colspan="1">1.47 (0.46)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FEV<sub>1</sub> (L) postbronchodilator (% predicted FEV<sub>1</sub>)</td><td valign="top" align="left" rowspan="1" colspan="1">61.357 (13.0941)</td><td valign="top" align="left" rowspan="1" colspan="1">60.268 (14.8594)</td><td valign="top" align="left" rowspan="1" colspan="1">61.300 (11.4672)</td><td valign="top" align="left" rowspan="1" colspan="1">57.600 (12.8797)</td><td valign="top" align="left" rowspan="1" colspan="1">57.474 (13.1376)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FEV<sub>1</sub> reversibility after inhalation of bronchodilator (%)</td><td valign="top" align="left" rowspan="1" colspan="1">20.167 (13.3543)</td><td valign="top" align="left" rowspan="1" colspan="1">18.829 (13.6874)</td><td valign="top" align="left" rowspan="1" colspan="1">17.000 (12.7481)</td><td valign="top" align="left" rowspan="1" colspan="1">23.800 (15.4026)</td><td valign="top" align="left" rowspan="1" colspan="1">15.737 (9.4331)</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-copd-11-2543"><p><bold>Note:</bold> Data are represented as mean (standard deviation) unless otherwise specified.</p></fn><fn id="tfn2-copd-11-2543"><label>*</label><p>Open label.</p></fn><fn id="tfn3-copd-11-2543"><p><bold>Abbreviations:</bold> IND, indacaterol; GLY, glycopyrronium; TIO, tiotropium; ICS, inhaled corticosteroid; FEV<sub>1</sub>, forced expiratory volume in 1 second; GOLD, Global Initiative for Chronic Obstructive Lung Disease.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-copd-11-2543" position="float"><label>Table 2</label><caption><p>Summary of AEs and SAEs by preferred terms in the Japanese subgroup</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"></th><th valign="top" align="left" rowspan="1" colspan="1">IND/GLY (n=42)</th><th valign="top" align="left" rowspan="1" colspan="1">IND (n=41)</th><th valign="top" align="left" rowspan="1" colspan="1">GLY (n=40)</th><th valign="top" align="left" rowspan="1" colspan="1">TIO (n=40)</th><th valign="top" align="left" rowspan="1" colspan="1">Placebo (n=19)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Total AEs</td><td valign="top" align="left" rowspan="1" colspan="1">21 (50.0)</td><td valign="top" align="left" rowspan="1" colspan="1">27 (65.9)</td><td valign="top" align="left" rowspan="1" colspan="1">24 (60.0)</td><td valign="top" align="left" rowspan="1" colspan="1">31 (77.5)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (63.2)</td></tr><tr><td colspan="6" valign="top" align="left" rowspan="1">AEs ≥2 incidences in any group</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> COPD<xref ref-type="table-fn" rid="tfn5-copd-11-2543">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1">5 (11.9)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (17.1)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (15.0)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (25.0)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (31.6)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Nasopharyngitis</td><td valign="top" align="left" rowspan="1" colspan="1">4 (9.5)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (24.4)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (22.5)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (22.5)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (26.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Cough</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4.8)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Productive cough</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4.8)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Constipation</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4.8)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4.9)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (7.5)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Bronchitis</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2.4)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">3 (7.5)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (5.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Upper respiratory tract infection</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2.4)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2.4)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">2 (5.0)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (5.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> GERD</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2.5)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Back pain</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">3 (7.5)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Drug-related AEs</td><td valign="top" align="left" rowspan="1" colspan="1">7 (16.7)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (12.2)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (10.0)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (12.5)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td></tr><tr><td colspan="6" valign="top" align="left" rowspan="1">AEs leading to permanent discontinuation of study drugs</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Total SAEs</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2.4)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (12.2)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (5.0)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2.5)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (10.5)</td></tr></tbody></table><table-wrap-foot><fn id="tfn4-copd-11-2543"><p><bold>Notes:</bold> Data are presented as number of patients (percentage).</p></fn><fn id="tfn5-copd-11-2543"><label>a</label><p>Includes COPD exacerbation or COPD worsening.</p></fn><fn id="tfn6-copd-11-2543"><p><bold>Abbreviations:</bold> AEs, adverse events; SAEs, serious adverse events; IND, indacaterol; GLY, glycopyrronium; TIO, tiotropium; GERD, gastroesophageal reflux disease.</p></fn></table-wrap-foot></table-wrap></floats-group></article>